

# HARMONi-7

If you are interested in the HARMONi-7 Clinical Study, please contact your doctor for more information.

Have you or someone you love been diagnosed with stage 4 non-small cell lung cancer (NSCLC) that has never been treated?



## About the HARMONi-7 Study

- **Randomized:** Patients are randomly assigned into different groups
- **Double-blind:** Neither the participants nor the doctors know who is receiving which treatment
- **Global, phase 3 clinical study** of ivonescimab versus pembrolizumab
- **Diagnosed with metastatic** (the cancer has spread), **non-small cell lung cancer** (mNSCLC)
- **For first-line treatment** (the patient has not been treated for mNSCLC)



# HARMONi-7



Learn more by visiting [ClinicalTrials.gov](https://ClinicalTrials.gov)  
(NCT06767514)

Or

Email [medinfo@smmmtx.com](mailto:medinfo@smmmtx.com)

Ivonescimab is an investigational drug being studied for its safety and effectiveness against the current standard treatment.



Summit Therapeutics and the Summit Therapeutics logo are trademarks of Summit Therapeutics Inc. Copyright 2026, Summit Therapeutics Inc. All Rights Reserved.

MAT-SMT112-0194 | Version 3.0 | 08 Apr 2026  
Protocol Amendment 1 | 19 Dec 2024



# HARMONi-7

## Have you or someone you love been diagnosed with stage 4 non-small cell lung cancer (NSCLC) that has never been treated?

If so, there is a phase 3 clinical study called HARMONi-7 that you may want to ask your doctor about.



### What is the purpose of this clinical study?

- The purpose of this study is to learn whether a new investigational treatment called ivonescimab will work and be safe for the treatment of NSCLC that has spread. The study will compare the investigational treatment with an approved treatment called pembrolizumab.

### What is the clinical study drug, ivonescimab?

- Ivonescimab is an investigational treatment, which works by blocking two separate targets in the body to decrease the cancer cells' ability to live, grow, and spread.

### Are you eligible for this clinical study?

- You may be eligible if you have been diagnosed with stage 4 NSCLC and you have not received any prior therapy. Please talk with your doctor to determine if you are eligible.

Your doctor can provide you with additional information but here are a few things to know:

- If you are eligible, what is involved? Once enrolled in the clinical study, you will visit the clinic every three weeks for infusions. The treatment may continue for up to 24 months.
- You will receive regular blood tests and scans of your tumor.
- You will be regularly asked about any side effects or safety concerns you have, including worsening symptoms of previous illness.

### If you are in the clinical study, will you receive ivonescimab?

- You will be randomly assigned to one of two treatment groups.
- Half the patients will be assigned to receive ivonescimab and the other half will receive pembrolizumab.
- Ivonescimab or pembrolizumab is administered by infusion (medication delivered into the body through the bloodstream instead of taking as pills or liquid).

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA).

# HARMONi-7

